Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
TG Therapeutics revenue
TG Therapeutics's revenue is $329.0 million.
What is TG Therapeutics's revenue?
- TG Therapeutics's revenue growth from 2012 to 2024 is 1,727,136.46%.
- TG Therapeutics has 286 employees, and the revenue per employee ratio is $1,150,363.
- TG Therapeutics's peak quarterly revenue was $165.8M in 2023(q3).
- TG Therapeutics peak revenue was $329.0M in 2024.
- TG Therapeutics annual revenue for 2023 was 233.7M, 8,290.02% growth from 2022.
- TG Therapeutics annual revenue for 2024 was 329.0M, 40.8% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
TG Therapeutics historical revenue
TG Therapeutics's peak revenue was $329.0M in 2024. The peak quarterly revenue was $165.8M in 2023(q3).
TG Therapeutics's revenue increased from $19.0k in 2012 to $329.0M currently. That's a 1,727,136.46% change in annual revenue.
TG Therapeutics annual revenue
TG Therapeutics annual revenue over time
| Fiscal year / year | TG Therapeutics revenue |
|---|---|
| 2012 | $19,048 |
| 2013 | $152,381 |
| 2014 | $152,381 |
| 2015 | $152,381 |
| 2016 | $152,381 |
| 2017 | $152,381 |
| 2018 | $152,000 |
| 2019 | $152,000 |
| 2020 | $152,000 |
| 2021 | $6.7M |
| 2022 | $2.8M |
| 2023 | $233.7M |
| 2024 | $329.0M |
Rate TG Therapeutics' financial transparency
TG Therapeutics annual growth
TG Therapeutics saw the greatest revenue growth in 2021, when revenue increased by 4,300.66%.
TG Therapeutics had the lowest revenue growth in 2022, when revenue changed by -58.36%.
TG Therapeutics annual growth rate over time
| Year | TG Therapeutics growth |
|---|---|
| 2013 | 700%↑ |
| 2014 | 0%↓ |
| 2015 | 0%↓ |
| 2016 | 0%↓ |
| 2017 | 0%↓ |
| 2018 | -0%↓ |
| 2019 | 0%↓ |
| 2020 | 0%↓ |
| 2021 | 4301%↑ |
| 2022 | -58%↓ |
| 2023 | 8290%↑ |
| 2024 | 41%↑ |
TG Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
TG Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | - | - | - | $19,092 |
| 2013 | $38,095 | $38,095 | $38,096 | $38,095 |
| 2014 | $38,095 | $38,095 | $38,096 | $38,095 |
| 2015 | $38,095 | $38,095 | $38,096 | $38,095 |
| 2016 | $38,095 | $38,095 | $38,096 | $38,095 |
| 2017 | $38,000 | $38,000 | $38,000 | $38,381 |
| 2018 | $38,000 | $38,000 | $38,000 | $38,000 |
| 2019 | $38,000 | $38,000 | $38,000 | $38,000 |
| 2020 | $38,000 | $38,000 | $38,000 | $38,000 |
| 2021 | $793,000 | $1.5M | $2.0M | $2.3M |
| 2022 | $2.0M | $594,000 | $94,000 | $80,000 |
| 2023 | $7.8M | $16.1M | $165.8M | $44.0M |
| 2024 | $63.5M | $73.5M | $83.9M | $108.2M |
TG Therapeutics jobs nearby
Do you work at TG Therapeutics?
Did TG Therapeutics meet its revenue projections?
TG Therapeutics financial information
| CEO | Michael Sean Weiss |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 286 |
| Date Founded | 1993 |
| Headquarters | New York, New York |
| Number of Locations | 1 |
| Revenue | $329.0M |
| Net Income | -$198,335,000 |
| Gross Proft | $290.5M (2024) |
| PE Ratio | 22.92 |
| Tax Rate | 0.1% |
| Market Capitalization | $535.9M |
| Total Assets | $193,572,000 |
| Ticker | TGTX |
TG Therapeutics jobs you might like
TG Therapeutics financing
TG Therapeutics received early financing of $25.0M on 2012-02-29.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $25M | 02/2012 |
| Post Ipo Debt | $60M | 02/2019 |
| Post Ipo Equity | $50M | 12/2019 |
| Post Ipo Debt | $70M | 01/2022 |
TG Therapeutics investors
| Investors | Security type |
|---|---|
| HERCULES CAPITAL INC | Post Ipo Debt |
| HERCULES CAPITAL INC | Post Ipo Debt |
TG Therapeutics competitors
TG Therapeutics's top competitor, Halozyme, earned an annual revenue of $1.0B.
TG Therapeutics's smallest competitor is Onconova Therapeutics with revenue of $226.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Geron | - | $77.0M | 15 | - |
| Syndax | - | $23.7M | 61 | - |
| Leap Therapeutics | - | $1.5M | 30 | - |
| Mustang Bio | - | $2.4M | 38 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| ChemoCentryx | - | $32.2M | 76 | - |
| InMed Pharmaceuticals | - | $1.6M | 20 | - |
| Aclaris Therapeutics | - | $18.7M | 60 | - |
| Halozyme | - | $1.0B | 136 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of TG Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about TG Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at TG Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by TG Therapeutics. The data presented on this page does not represent the view of TG Therapeutics and its employees or that of Zippia.
TG Therapeutics may also be known as or be related to MANHATTAN PHARMACEUTICALS INC, TG THERAPEUTICS INC., TG Therapeutics, TG Therapeutics Inc, TG Therapeutics, Inc. and Tg Therapeutics, Inc.